APELOA Sustainability Profile
APELOA, officially known as APELOA Pharmaceutical Co., Ltd., is a prominent player in the pharmaceutical industry, headquartered in China (CN). Founded in 2001, the company has established a strong presence in major operational regions across Asia and beyond, focusing on the development and manufacturing of high-quality generic drugs and active pharmaceutical ingredients (APIs). With a commitment to innovation, APELOA offers a diverse portfolio of products, including oncology medications and cardiovascular treatments, distinguished by their rigorous quality standards and competitive pricing. The company has achieved significant milestones, including numerous certifications and partnerships that enhance its market position. Recognised for its dedication to research and development, APELOA continues to contribute to global healthcare solutions, solidifying its reputation as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does APELOA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
APELOA's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
APELOA's reported carbon emissions
In 2024, APELOA reported total carbon emissions of approximately 615,600,000 kg CO2e, which includes about 10,400,000 kg CO2e from Scope 1 emissions and approximately 605,200,000 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions. Despite the significant emissions figures, APELOA has not established specific reduction targets or climate pledges, indicating a potential area for future commitment. The emissions data is directly sourced from APELOA Pharmaceutical Co., Ltd, with no cascading from a parent or related organization. As APELOA continues to operate within the pharmaceutical industry, addressing its carbon footprint will be crucial for aligning with global climate initiatives and enhancing sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | |
|---|---|
| Scope 1 | 10,400,000 |
| Scope 2 | 605,200,000 |
| Scope 3 | - |
How Carbon Intensive is APELOA's Industry?
How Carbon Intensive is APELOA's Location?
APELOA's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
APELOA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
